Madrigal Pharmaceuticals Inc.
Common Stock · USD · NASDAQ
Price
$524.72
Cap
$814.36B
Earnings
—
30d Trend
+1.4%
43% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 50×Macro 0.99 (−1%)=50
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
3-6 month opportunity — emerging trend
BRAIN47'S ASSESSMENT
I rate Madrigal Pharmaceuticals Inc. at 50/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 62/100. I classify this as a speculative position with the strongest thesis on a medium-term horizon.
PAST PERFORMANCE
1 MONTH
-0.5%
3 MONTHS
+19.4%
12 MONTHS
+91.1%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
3-6 month opportunity — emerging trend. Momentum (62) and Technical (49) are the primary strengths. I note that fundamentals is the weakest area at 15/100 — this warrants monitoring. Historical volatility is elevated at 43%. I classify this as a speculative position — elevated volatility at 43% and asymmetric payoff potential define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.